Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy

Miguel J Franquiz,1,2 Nicholas J Short2 1Baylor College of Medicine, Houston, TX, USA; 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Franquiz MJ, Short NJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	“blinatumomab” “bispecific antibodies” “acute lymphoblastic leukemia” “precursor cell lymphoblastic leukemia-lymphoma” “adult” “b-cell leukemia” Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b9e001d564a746c382b36167e8ef2ca5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b9e001d564a746c382b36167e8ef2ca5
record_format	dspace
spelling	oai:doaj.org-article:b9e001d564a746c382b36167e8ef2ca52021-12-02T11:04:57ZBlinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy1177-5491https://doaj.org/article/b9e001d564a746c382b36167e8ef2ca52020-02-01T00:00:00Zhttps://www.dovepress.com/blinatumomab-for-the-treatment-of-adult-b-cell-acute-lymphoblastic-leu-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Miguel J Franquiz,1,2 Nicholas J Short2 1Baylor College of Medicine, Houston, TX, USA; 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 428, Houston, TX 77030, USATel +1-713-563-4485Email nshort@mdanderson.orgAbstract: Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, has resulted in improved outcomes in both relapsed/refractory and minimal residual disease-positive B-cell ALL. Promising emerging data also demonstrate the efficacy of this agent in the frontline setting and in combination regimens. Uncertainty remains regarding the optimal sequencing and combination of blinatumomab with cytotoxic chemotherapy and other emerging agents. The pharmacology and clinical data on blinatumomab for adult B-cell ALL, both as monotherapy and in combinations, will be reviewed herein.Keywords: blinatumomab, bispecific antibodies, acute lymphoblastic leukemia, precursor cell lymphoblastic leukemia-lymphoma, adult, B-cell leukemiaFranquiz MJShort NJDove Medical Pressarticle“blinatumomab”“bispecific antibodies”“acute lymphoblastic leukemia”“precursor cell lymphoblastic leukemia-lymphoma”“adult”“b-cell leukemia”Medicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 14, Pp 23-34 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	“blinatumomab” “bispecific antibodies” “acute lymphoblastic leukemia” “precursor cell lymphoblastic leukemia-lymphoma” “adult” “b-cell leukemia” Medicine (General) R5-920
spellingShingle	“blinatumomab” “bispecific antibodies” “acute lymphoblastic leukemia” “precursor cell lymphoblastic leukemia-lymphoma” “adult” “b-cell leukemia” Medicine (General) R5-920 Franquiz MJ Short NJ Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
description	Miguel J Franquiz,1,2 Nicholas J Short2 1Baylor College of Medicine, Houston, TX, USA; 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 428, Houston, TX 77030, USATel +1-713-563-4485Email nshort@mdanderson.orgAbstract: Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, has resulted in improved outcomes in both relapsed/refractory and minimal residual disease-positive B-cell ALL. Promising emerging data also demonstrate the efficacy of this agent in the frontline setting and in combination regimens. Uncertainty remains regarding the optimal sequencing and combination of blinatumomab with cytotoxic chemotherapy and other emerging agents. The pharmacology and clinical data on blinatumomab for adult B-cell ALL, both as monotherapy and in combinations, will be reviewed herein.Keywords: blinatumomab, bispecific antibodies, acute lymphoblastic leukemia, precursor cell lymphoblastic leukemia-lymphoma, adult, B-cell leukemia
format	article
author	Franquiz MJ Short NJ
author_facet	Franquiz MJ Short NJ
author_sort	Franquiz MJ
title	Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
title_short	Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
title_full	Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
title_fullStr	Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
title_full_unstemmed	Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
title_sort	blinatumomab for the treatment of adult b-cell acute lymphoblastic leukemia: toward a new era of targeted immunotherapy
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/b9e001d564a746c382b36167e8ef2ca5
work_keys_str_mv	AT franquizmj blinatumomabforthetreatmentofadultbcellacutelymphoblasticleukemiatowardaneweraoftargetedimmunotherapy AT shortnj blinatumomabforthetreatmentofadultbcellacutelymphoblasticleukemiatowardaneweraoftargetedimmunotherapy
_version_	1718396311867228160

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy

Ejemplares similares